Skip to main content
MRNA
NASDAQ Life Sciences

Moderna 预计年末现金为 45 亿美元 - 50 亿美元，披露 Q1 支付 9.5 亿美元的和解费用

feedReported by Reuters
Sentiment info
Neutral
Importance info
8
Price
$54.81
Mkt Cap
$19.68B
52W Low
$22.28
52W High
$55.2
Market data snapshot near publication time

summarizeSummary

Moderna 更新了其财务预测，目前预计 2026 年年末现金和现金等价物将在 4.5 亿美元至 5 亿美元之间，总预计流动性在 5.4 亿美元至 5.9 亿美元之间。关键是，该公司还预计在 2026 年第一季度记录一笔重大 9.5 亿美元的费用，相关于和解支付。这一更新在 2 月 20 日提交的 10-K 报告之后提供了更具体的前瞻性财务细节，该报告概述了 2025 年的结果和更广泛的财务计划。在 9.5 亿美元的费用是一项对 Q1 有重大影响的一次性支出时，强劲的预计流动性和公司宣布的 2026 年和 2028 年实现收支平衡的收入增长路径提供了对其财务健康的平衡视图。交易者将在未来的财报中关注和解的进一步细节以及朝着这些财务目标的进展，特别是在 EBITDA、GAAP 和 SEC 的报告中，如 Form 4 和 8-K，以及 CIK 的相关披露中。

在该公告发布时，MRNA的交易价格为$54.81，交易所为NASDAQ，所属行业为Life Sciences，市值约为$196.8亿。 52周交易区间为$22.28至$55.20。 这则新闻被评估为中性市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed MRNA - Latest Insights

MRNA
Apr 21, 2026, 9:40 AM EDT
Source: Access Newswire
Importance Score:
8
Moderna's mCOMBRIAX, World's First Flu-COVID Combo Vaccine, Gets EU Marketing Authorization
Sentiment: Positive
View Wiseek Article
MRNA
Mar 13, 2026, 6:58 AM EDT
Source: Reuters
Importance Score:
8
GSK's RSV Vaccine Gains Key FDA Approval for Younger Adults, Intensifying Competition for Moderna
Sentiment: Negative
View Wiseek Article
MRNA
Mar 04, 2026, 8:20 PM EST
Filing Type: 8-K
Importance Score:
8
Moderna Settles Patent Litigation for Up to $2.25B, Securing Royalty-Free Rights for Key Vaccines
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 04, 2026, 10:10 AM EST
Source: Dow Jones Newswires
Importance Score:
9
Moderna Settles Major Covid-19 Vaccine Patent Suit for $2.25 Billion, Shares Rise
Sentiment: Positive
View Wiseek Article
MRNA
Mar 03, 2026, 4:28 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Moderna to Appeal to Federal Circuit Court, Citing Government-Contractor Immunity Defense
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 4:25 PM EST
Source: Reuters
Importance Score:
8
Moderna Projects $4.5B-$5B Year-End Cash, Reveals $950M Q1 Settlement Charge
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 3:04 PM EST
Source: Wiseek News
Importance Score:
8
Moderna's Cancer Vaccine Shows Reduced Recurrence, FDA Reverses Flu Vaccine Review
Sentiment: Positive
View Wiseek Article
MRNA
Feb 27, 2026, 7:00 AM EST
Source: Acceswire
Importance Score:
8
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Sentiment: Positive
View Wiseek Article
MRNA
Feb 20, 2026, 4:02 PM EST
Filing Type: 10-K
Importance Score:
8
Moderna Reports $2.8B Net Loss in 2025 Amidst 40% Revenue Decline, Discontinues CMV Vaccine in Congenital CMV
Sentiment: Negative
View Wiseek Article
MRNA
Feb 13, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
7
Moderna Reports Q4 & FY25 Results, Projects 10% Revenue Growth in 2026, Faces US Flu Vaccine Setback
Sentiment: Neutral
View Wiseek Article